The sharp improvement in financials and extended cash runway support continued R&D advancement and de-risk the near-term outlook. Traders should monitor the mid-2026 decision point on opting into a 40% U.S. cost-profit share with Gilead for the HPI program, which could significantly impact future profit potential.
Price Chart
Executive Summary
Assembly Biosciences reported strong financial results for 2025, highlighted by a significant increase in collaboration revenue from Gilead to $72.3 million and a net loss reduction to $6.1 million from $40.2 million in 2024. The company also secured a $35 million option fee from licensing its herpes HPI program to Gilead and now holds $248.1 million in cash, projecting runway into 2028.
Key Financial Metrics
Key Facts
- Collaboration revenue increased to $72.3 million in 2025 from $28.5 million in 2024, driven by Gilead funding.
- Net loss narrowed sharply to $6.1 million in 2025 from $40.2 million in 2024.
- Cash, cash equivalents, and marketable securities totaled $248.1 million as of December 31, 2025, up from $112.1 million a year earlier.
- Received $35 million net option fee from Gilead for licensing the HPI program (ABI-5366 and ABI-1179) for recurrent genital herpes.
- Gilead declined option on HBV candidate ABI-4334, which Assembly Bio will now seek to partner independently.
- Phase 2 initiation for HDV candidate ABI-6250 expected by end of 2026.
Financial Impact
Revenue up 154% YoY; net loss reduced by 85%; cash position increased by $136 million year-over-year.
Risk Factors
- ABI-5366, ABI-1179, ABI-6250, and ABI-4334 remain investigational with no guaranteed approval.
- Gilead's decision not to pursue ABI-4334 increases uncertainty around the HBV program's future.
- Future milestones depend on clinical trial execution, which carries inherent development risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259423 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 10w ago | Institutional Cluster | $30.01 $35.28 | ▲ +17.56% | ▲ +18.75% | $20.30 (−32.36%) |
Aug 13, 2026 10w ago | Press Release | $32.95 $34.38 | ▲ +4.34% | ▲ +5.71% | $20.30 (−38.39%) |
Jun 11, 2026 19w ago | Institutional Cluster | $22.53 $24.15 | ▲ +7.19% | ▲ +6.76% | $20.30 (−9.90%) |
Jun 5, 2026 20w ago | 8-K | $22.56 $23.34 | ▲ +3.48% | ▲ +1.37% | $20.30 (−10.00%) |
May 22, 2026 22w ago | 424B5 | $28.75 $26.92 | ▲ +6.37% | ▲ +7.45% | $20.30 (+29.39%) |
May 22, 2026 22w ago | 8-K | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.30 (−28.37%) |
May 22, 2026 22w ago | Press Release | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.30 (−28.37%) |
May 7, 2026 24w ago | Press Release | $29.74 $30.30 | ▲ +1.88% | ▲ +0.42% | $20.30 (−31.74%) |
Mar 30, 2026 30w ago | EFFECT | $26.64 $28.53 | ▲ +7.09% | ▲ +2.79% | $20.30 (−23.80%) |
Mar 19, 2026 31w ago | Press Release | $28.46 $27.70 | ▼ −2.67% | ▼ −0.52% | $20.30 (−28.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers